Mizuho Reaffirms Buy Rating for Viewray (NASDAQ:VRAY)

Mizuho reiterated their buy rating on shares of Viewray (NASDAQ:VRAY) in a research report sent to investors on Sunday, AnalystRatings.com reports. They currently have a $9.00 target price on the stock.

VRAY has been the subject of several other research reports. Piper Jaffray Companies started coverage on shares of Viewray in a research report on Tuesday, June 18th. They set an overweight rating and a $15.00 price target for the company. Jefferies Financial Group lowered their price target on shares of Viewray from $14.00 to $7.00 and set a buy rating for the company in a research report on Friday, August 9th. ValuEngine lowered shares of Viewray from a buy rating to a hold rating in a research report on Saturday. BidaskClub lowered shares of Viewray from a sell rating to a strong sell rating in a research report on Thursday, August 8th. Finally, Cantor Fitzgerald set a $13.00 price target on shares of Viewray and gave the stock a buy rating in a research report on Tuesday, May 28th. Two investment analysts have rated the stock with a sell rating, two have given a hold rating and eight have given a buy rating to the company’s stock. Viewray currently has a consensus rating of Buy and an average price target of $11.95.

Viewray stock opened at $4.01 on Friday. The business’s 50-day moving average price is $8.26. The company has a market capitalization of $305.29 million, a price-to-earnings ratio of -4.09 and a beta of 0.79. The company has a quick ratio of 3.21, a current ratio of 4.28 and a debt-to-equity ratio of 0.47. Viewray has a one year low of $2.76 and a one year high of $10.73.



Viewray (NASDAQ:VRAY) last released its quarterly earnings results on Thursday, August 8th. The company reported ($0.32) EPS for the quarter, missing the consensus estimate of ($0.23) by ($0.09). The firm had revenue of $30.17 million for the quarter, compared to the consensus estimate of $25.92 million. Viewray had a negative return on equity of 62.98% and a negative net margin of 128.13%. The firm’s revenue was up 83.5% on a year-over-year basis. During the same quarter in the prior year, the company posted ($0.30) EPS. As a group, research analysts expect that Viewray will post -1.01 earnings per share for the current year.

In related news, insider James F. Dempsey sold 21,615 shares of the company’s stock in a transaction dated Thursday, August 1st. The shares were sold at an average price of $8.97, for a total value of $193,886.55. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO Scott William Drake acquired 131,260 shares of Viewray stock in a transaction that occurred on Tuesday, August 13th. The stock was bought at an average cost of $3.81 per share, with a total value of $500,100.60. The disclosure for this purchase can be found here. Corporate insiders own 15.48% of the company’s stock.

A number of hedge funds have recently bought and sold shares of VRAY. Bank of Montreal Can lifted its holdings in Viewray by 4,390.1% in the second quarter. Bank of Montreal Can now owns 5,882 shares of the company’s stock worth $52,000 after purchasing an additional 5,751 shares during the period. Cutler Group LP acquired a new stake in Viewray in the first quarter worth about $76,000. BNP Paribas Arbitrage SA lifted its holdings in Viewray by 57,004.3% in the first quarter. BNP Paribas Arbitrage SA now owns 13,134 shares of the company’s stock worth $97,000 after purchasing an additional 13,111 shares during the period. Bray Capital Advisors acquired a new stake in Viewray in the first quarter worth about $104,000. Finally, Stephens Inc. AR acquired a new stake in Viewray in the first quarter worth about $117,000.

Viewray Company Profile

ViewRay, Inc designs, manufactures and markets MRIdian, the magnetic resonance imaging (MRI)-guided radiation therapy system to image and treat cancer patients simultaneously. The Company offers radiation therapy technology combined with magnetic resonance imaging. MRIdian integrates MRI technology, radiation delivery and the Company’s software to locate, target and track the position and shape of soft-tissue tumors while radiation is delivered.

Recommended Story: Bull Market

Analyst Recommendations for Viewray (NASDAQ:VRAY)

Receive News & Ratings for Viewray Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Viewray and related companies with MarketBeat.com's FREE daily email newsletter.